MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$3,088K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Accounts payable
Accrued expenses
Stock-based compensation
Others
Negative Cash Flow Breakdown
Net loss
Deferred research and developmen...
Change in fair value of continge...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-3,217
-2,044
-1,996
-4,361
Stock-based compensation
135
135
153
228
Change in fair value of contingent consideration
-212
27
-775
633
Loss on asset disposal
-
-
1
-
Non-cash lease expense
111
143
139
134
Depreciation
24
24
27
28
Deferred research and development tax credit
-415
-417
1,118
-455
Prepaid expenses and other current assets
26
-428
410
-251
Accounts payable
389
-397
209
161
Accrued expenses
223
-27
-891
-784
Payment of contingent consideration
-
-
-500
-500
Accrued employee benefits
25
-172
-308
-9
Proceeds from issuance common stock and warrants offering, net of issuance costs
-
-
6,690
-
Operating lease liability
-122
-156
-149
-145
Proceeds from warrant inducement
-
-
3,942
-
Net cash used in operating activities
-3,085
-2,456
-2,882
-4,319
Proceeds from issuance of common stock
-
-
-
0
Proceeds from long term debt
-
-
15
34
Purchase of property and equipment
3
-
0
19
Proceeds from issuance of common stock for warrant exercises
-
-
0
0
Net cash used in investing activities
-3
-
0
-19
Tax credit receivable
-3
1,612
-1,552
41
Payment of loans payable
-11
-49
-1
-2
Proceeds from issuance of common stock under at - the - market offering, net of issuance cost
0
2,303
6,554
279
Net cash provided by financing activities
-14
3,866
8,458
-148
Effects of exchange rate changes on cash and cash equivalents
7
-36
-48
-106
Net increase (decrease) in cash and cash equivalents and restricted cash
-3,095
1,374
5,528
-4,592
Cash, cash equivalents and restricted cash at the beginning of this period
14,476
13,102
7,574
11,705
Cash, cash equivalents and restricted cash at the end of this period
11,381
-
-
-
Cash and cash equivalents
11,337
-
-
-
Restricted cash included in other long-term assets
44
-
-
-
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows
11,381
14,476
13,102
7,574
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Effects of exchange rate
changes on cash and cash...
$7K
(-88.71%↓ Y/Y)
Net increase
(decrease) in cash and cash...
-$3,095K
(-771.37%↓ Y/Y)
Canceled cashflow
$7K
Accounts payable
$389K
(229.24%↑ Y/Y)
Accrued expenses
$223K
(137.04%↑ Y/Y)
Stock-based compensation
$135K
(-50.55%↓ Y/Y)
Non-cash lease expense
$111K
(-55.42%↓ Y/Y)
Accrued employee
benefits
$25K
(105.85%↑ Y/Y)
Depreciation
$24K
(-54.72%↓ Y/Y)
Net cash used in
operating activities
-$3,085K
(67.42%↑ Y/Y)
Net cash provided by
financing activities
-$14K
(-100.14%↓ Y/Y)
Canceled cashflow
$907K
Net cash used in
investing activities
-$3K
(81.25%↑ Y/Y)
Net loss
-$3,217K
(81.49%↑ Y/Y)
Payment of loans payable
-$11K
(83.58%↑ Y/Y)
Tax credit
receivable
-$3K
(-100.17%↓ Y/Y)
Deferred research and
development tax credit
-$415K
(51.23%↑ Y/Y)
Change in fair value of
contingent consideration
-$212K
(-102.31%↓ Y/Y)
Operating lease liability
-$122K
(54.48%↑ Y/Y)
Prepaid expenses and
other current assets
$26K
(104.23%↑ Y/Y)
Purchase of property and
equipment
$3K
(-81.25%↓ Y/Y)
Buy us a coffee
Theriva Biologics, Inc. (TOVX)
Theriva Biologics, Inc. (TOVX)